• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Histogenics plunges on missed endpoint in NeoCart trial

Histogenics plunges on missed endpoint in NeoCart trial

September 5, 2018 By Brad Perriello

HistogenicsUPDATE: Now includes comment from CEO Adam Gridley

Histogenics (NSDQ:HSGX) said today that a pivotal trial of its regenerative NeoCart knee treatment failed to meet its primary endpoint, sending its share price down some -70%.

Waltham, Mass.-based Histogenics said NeoCart, which is designed to repair knee cartilage damage using cells harvested from the surface of patients’ femur, missed the study’s primary endpoint of statistically significant improvement in pain and function at one year compared with micro-fracture.

The prospective, randomized study used the Knee Injury & Osteoarthritis Outcomes Score and the International Knee Documentation Committee score for the main endpoint of at least a 12-point improvement in the KOOS pain sub-score assessment and a 20-point improvement in the IKDC subjective assessment.

In the intention-to-treat analysis, 121 of 170 patients in the NeoCart arm, or 71.2%, showed a positive response, compared with 49 of 79 or 62.0% of the control arm.

The news sent HSGX shares down -72.2% to 77¢ apiece today in early trading.

Despite the missed primary endpoint, CEO Adam Gridley said that he’s still optimistic about the future of the NeoCart knee treatment, and the data that came from the trial.

“We’re quite proud of completing the single biggest trial enrolled prospectively with the FDA’s guidelines, which are pretty narrowly defined for these knee cartilage treatments. We ran a really solid trial. We also had a very, very tough dual threshold responder analysis. We literally missed by about two patients, and the totality of that dual threshold data also showed clinically meaningful responses, both early and sustained for NeoCart,” Gridley told MassDevice.com “We’re walking away both proud and optimistic, and the feedback from our surgeons and patients continues to be fantastic.”

Gridley said that Histogenics will continue to work with the FDA, and that he expects they will have a meeting with the company within, roughly, the next 30 days.

“It’s full speed ahead for us. We had originally planned on a [Biologics License Application] at the end of this year or early 2019. I think based on this data, we still have those plans, and we’re trying to bring the product to market in early 2020 as originally anticipated. So, we have a lot of work to do, but we’ll work closely with the agency to make sure we’re aligned,” Gridley said.

Gridley didn’t downplay the impact of the missed endpoint, but did say that the company designed the trials a decade prior, and suggested that the endpoint was “a step above anything that has been tried in orthopedics.”

“Now, we designed this, so we own this, but we designed this 10 years ago when there was a lot of uncertainty on what was the best way to run pain and function trials in knee cartilage. It was a very different spot from a regulatory perspective,” Gridley said. “I think it was a great design, but I think it’s two or three logarithmic steps above what the FDA now, 10 years later, is requiring for approval.”

Gridley said that he is optimistic that the NeoCart treatment will be an overall improvement upon the current standard of care, micro-fracture, and that Neocart has the potential to be a great benefit to the average patient.

He also offered that surgeons involved with the NeoCart system in the trial continue to laud the system and the results they’ve seen from it in their patients.

“May of the surgeons in both our phase two and phase three trials are calling us saying ‘my patients are thrilled – they got their life back, they got it back earlier, and they’re doing things that they couldn’t do before,’” Gridley said. “This is all about the patient. They’re all looking for better alternatives, and over half of the patients that get these injuries just don’t do anything because when they see micro-fracture is the option, they say ‘I’m better off just waiting and getting OA’.”

“We are pleased with the overall performance of NeoCart in this Phase 3 clinical trial and the data confirm the feedback we have received from several of the investigators who participated in the trial. Most importantly, patients treated with NeoCart displayed an early and sustained recovery from pain and return to function that was clinically meaningful. The data from this trial are also consistent with results seen in prior clinical trials of NeoCart as well as the biomechanical data generated as part of our collaboration with Cornell University,” added chief medical officer Dr. Lynne Kelley. “While we are continuing to analyze the data, we have already seen a number of important results, including a statistically significant improvement of NeoCart compared to micro-fracture in lesion sizes of greater than 2cm and patients with higher body mass index. We think that results such as these will be an important part of our planned discussions with the FDA, as well as with clinicians if NeoCart is approved.”

Filed Under: Clinical Trials, Orthopedics, Regenerative Medicine, Wall Street Beat Tagged With: Histogenics

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy